Crinetics Pharmaceuticals, Inc.
CRNX
Ранг среди акций
#2239
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Цена акции
$84.95
Последняя синхронизация: 2026-09-01
Рыночная капитализация
$9.00B
Изменение (1 день)
0.00%
Изменение (1 год)
100.12%
Страна
US
Торговля Crinetics Pharmaceuticals, Inc. (CRNX)
Категория
Healthcare
EPS для Crinetics Pharmaceuticals, Inc. (CRNX)
EPS по состоянию на June 2026 TTM: $-5.05
Согласно последним финансовым отчетам и цене акций Crinetics Pharmaceuticals, Inc., текущий EPS компании (TTM) составляет $-5.05. В конце 2023 EPS компании составлял $-3.69, больше, чем показателю 2022 года, равному $-3.15.
История EPS компании Crinetics Pharmaceuticals, Inc. с 2016 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2026 (TTM) | $-5.05 | 36.86% |
| 2024 | $-3.69 | 0.00% |
| 2023 | $-3.69 | 17.14% |
| 2022 | $-3.15 | 12.50% |
| 2021 | $-2.80 | 15.70% |
| 2020 | $-2.42 | 18.05% |
| 2019 | $-2.05 | -8.07% |
| 2018 | $-2.23 | 237.88% |
| 2017 | $-0.66 | 53.49% |
| 2016 | $-0.43 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $17.32 | -442.97% |
US
|
|
| $-7.98 | 58.02% |
US
|
|
| $-5.29 | 4.75% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -649.31% |
NL
|
